How to Buy Travere Therapeutics Stock
Travere Therapeutics Inc
Travere Therapeutics, Inc. , a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.
Travere Therapeutics stock last closed at $20.08, up 3.72% from the previous day, and has increased 267.77% in one year. It has overperformed other stocks in the Biotechnology industry by 3.45 percentage points. Travere Therapeutics stock is currently +262.45% from its 52-week low of $5.54, and -20.6% from its 52-week high of $25.29.
There are currently 88.74M TVTX shares outstanding. The market capitalization of TVTX is $1.78B. In the last 24 hours, 1.18M TVTX shares were traded.
How to Buy Travere Therapeutics Stock
Wondering how to invest in Travere Therapeutics stock? Here's how.
- Choose where to buy Travere Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Travere Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Pick your method of payment and add your info.
- Evaluate Travere Therapeutics stock: The Travere Therapeutics ticker symbol is TVTX. Is Travere Therapeutics stock a good investment? Should you buy shares of TVTX? How do TVTX's underlying business fundamentals look? Do top analysts think Travere Therapeutics is a good buy? Why has TVTX's stock price moved recently? (Hint: Our stock market analysis website can help you decide if TVTX is a good stock to buy).
- Place your TVTX buy order: Decide if you will purchase TVTX shares at the current market price or use a limit order to buy TVTX shares at a specific price.
- Watch your investment in TVTX: Create a watchlist to watch your investment in Travere Therapeutics shares.
Step 1: Choose where to buy Travere Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy TVTX shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
- Access to world markets: From Tech to Real Estate, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the right brokerage, you'll need to fill out some personal information so you can invest in TVTX stock today.
How to Open a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal details to start a new brokerage account.
- Submit your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've created your account on a good stock buying app, you can securely and quickly fund your account:
Watch the tutorial below for more details depositing money into your brokerage account.
Step 4: Evaluate Travere Therapeutics stock
After you have figured out the best place to buy Travere Therapeutics stock, it's very important to evaluate their stock prior to investing, so you truly wrap your head around the risk and upside.
Travere Therapeutics stock data
TVTX Due Diligence Checks
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in less time.
You can see all of the due diligence checks on TVTX's stock page.
Is TVTX stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge TVTX's true value.
Using relative valuations methods:
- TVTX may be overvalued based on its P/B ratio of 30.16x, relative to Biotechnology industry P/B ratio of 4.37x
You can do additional valuation analysis on TVTX's stock here.
How do TVTX Financials look?
Positive Health Checks:
- TVTX has cash burn of 273687000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the TVTX balance sheet.
- There are more short-term assets than short-term liabilities on the TVTX balance sheet.
Negative Health Checks:
- TVTX profit margin has gone down from -76.7% to -137.9% in the past year.
- Total TVTX debt is higher than 5 years ago, relative to shareholder equity.
- TVTX has a relatively high debt to equity ratio of 9.06.
- TVTX has $370.70M in cash and short term investments. This is not sufficient to cover its annual cash burn of $273.69M.
Do analysts think it's a good time to buy TVTX stock
Out of 9 Equities analysts who give ratings on TVTX, the consensus analyst rating on Travere Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest TVTX Analyst Recommendations
Liisa Bayko, a top 8% analyst from Evercore ISI Group maintains TVTX with a buy rating and raises their TVTX price target from $33.00 to $45.00, on Feb 12, 2025.
Ed Arce, a top 10% analyst from HC Wainwright & Co. maintains TVTX with a buy rating and raises their TVTX price target from $18.00 to $22.00, on Jan 15, 2025.
Allison Bratzel, a top 14% analyst from Piper Sandler maintains TVTX with a hold rating and raises their TVTX price target from $12.00 to $22.00, on Nov 14, 2024.
Carter Gould, a top 13% analyst from Barclays maintains TVTX with a strong buy rating and raises their TVTX price target from $18.00 to $20.00, on Nov 1, 2024.
Barclays's Carter Gould raised their price target on Travere Therapeutics (NASDAQ: TVTX) by 11.1% from $18 to $20 on 2024/11/01. The analyst maintained their Strong Buy rating on the stock.
Travere Therapeutics reported its Q3 2024 earnings.
Gould highlighted that "Filspari beat in the face of a slow-down in new starts."
Earnings Report
For Q3 2024, Travere Therapeutics reported:
- Loss per share of $0.70, which was in line with the Zacks Consensus Estimate and beat Q3 2023's loss of $1.17.
- Revenue of $62.9M, which beat the Zacks Consensus Estimate by 4.10% and Q3 2023's $37.1M.
Management did not provide financial guidance in its press release.
President & CEO Eric Dube, Ph.D., commented: “Our performance in the third quarter was exceptional.
"FILSPARI received full approval as the only medicine that can provide superior preservation of kidney function and replace current standard of care in IgAN, and our commercial team delivered strong growth in sales of FILSPARI in the U.S.
"Additionally, I am pleased to report that in the weeks since full approval we have seen a meaningful increase in demand, supporting our expectation that the broader label granted upon full approval coupled with the recent draft KDIGO guidelines will strengthen FILSPARI’s growth.
“As we look ahead, we are very well-positioned to further accelerate our growth with FILSPARI. At ASN Kidney Week, we illustrated the potential benefits of using FILSPARI as a first-line treatment, and presented data in combination with other therapies.
"Our European partner CSL Vifor has launched FILSPARI commercially in the first EU countries.
"And following the recent PARASOL group recommendation of a proteinuria-based clinical trial endpoint for FSGS, we have scheduled a meeting with the FDA to discuss a potential path forward for FILSPARI in FSGS.”
You can dive deeper into what analysts are forecasting on the Travere Therapeutics stock forecast page.
TVTX Momentum
How are TVTX Revenues/Earnings doing?
Last year, TVTX revenue was $233.18M. During the last 5 year, TVTX's revenue has increased by 5.87% per year. This was slower than the Biotechnology industry average of 45.47%.
Learn more about TVTX's earnings and revenue performance here.
What are TVTX executives and large shareholders up to?
In the past year, executives and large shareholders at TVTX have sold more shares than they have bought.
Christopher R. Cline, CHIEF FINANCIAL OFFICER of TVTX, was the latest TVTX insider to sell. They sold $630.96 worth of TVTX shares on Apr 11, 2025.
Learn more about who owns TVTX shares here.
Does TVTX stock generate passive income?
No, Travere Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about TVTX
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your TVTX buy order
You have two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at a given dollar amount, use a limit order.
Press the Open button and eToro will place your order.
If you want additional assistance buying stocks on eToro, watch the how to video below:
Step 6: Watch your investment in TVTX
Now that you own some TVTX stock, you'll want to stay up-to-date on your stock purchase.
Make a watchlist to see the latest developments about your TVTX stock.
TVTX Feed
How to Buy Stock in Travere Therapeutics
To reiterate, here are the 6 steps you need to take to buy Travere Therapeutics stock right now:
- Choose where to buy Travere Therapeutics stock
- Sign up for your brokerage account
- Deposit funds into your investment account
- Evaluate Travere Therapeutics stock
- Place your TVTX buy order
- Watch your investment in TVTX
If you are looking for a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to get notifications regarding your new investment in Travere Therapeutics, get started below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.